[{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"JR-141","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"alpha L Idosiduronase","moa":"Dermatan sulfate hydrolytic enzyme","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"alpha L Idosiduronase","moa":"Dermatan sulfate hydrolytic enzyme","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JR-141","moa":"Transferrin receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JR-141","moa":"Transferrin receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"alpha L Idosiduronase","moa":"Dermatan sulfate hydrolytic enzyme","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Pabinafusp Alfa","moa":"Transferrin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Takeda"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pabinafusp Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pabinafusp Alfa","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pabinafusp Alfa","moa":"Transferrin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Angelini Pharma"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"JCR Pharmaceuticals \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lepunafusp Alfa","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"JR-441","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Modalis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Modalis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"JCR Pharmaceuticals \/ Modalis Therapeutics"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"AAV-mediated Gene Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"JR-441","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"JR-446","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Medipal Holdings Corporation"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"JR-441","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"JR-441","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"JR-446","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Medipal Holdings Corporation"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Redalsomatropin Alfa","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Modalis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Modalis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"JCR Pharmaceuticals \/ Modalis Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by JCR Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
